

CURRICULUM VITAE 2023

1. GENERAL BIOGRAPGICAL INFORMATION:

NAME: Khalid Abdel-Rahman Khalil Halahleh

Contact Information:

Office Address: Department of Internal Medicine

Division of Medical Oncology Hematology-Bone Marrow Transplantation Program

King Hussein Cancer Center

P.O. Box 1269 Aljubeiha, Amman, 11941 Jordan

Tel (962-6)530-0460 Ext: 1554

Fax: (962-6)5526105

Mobile: +962-798954045

Kh.06314@khcc.jo

khalahleh@yahoo.com

Languages:

- Arabic (native).
- English, excellent in reading, writing and Fluent.
- Russian, excellent in reading, writing and fluent.
- Hebro, good in reading and printing, speaking

2. Medical Education:

School: Rostov on Done Medical University

Degree: MBBS

Date: 1992-1999

3. Post-Graduate Training:

Institution: Makassed Islamic Charitable Hospital

Position : Rotating Intern

Dates : 07/1999—08/2000

Institution: Ramallah Medical Complex

Position : Transitional resident of internal Medicine

Dates : 08/2000-02/2001

Institution: Augusta-Victoria Hospital

Position : Internal medicine Resident

Date : 03/2001-07/2003

Institution: King Hussein Cancer Center

Position: Medical Oncology Fellow

Date: 07/2003- 07/2006

Institution: Islamic Hospital

Position : Senior Internal Medicine resident

Date : 08/2006- 7/2007

Institution : Hadassah Medical center

Position : Bone Marrow Transplantation Fellow

Date : 08/2008-09/2009

4. Clinical Experience:

Institution: Augusta-Victoria Hospital Cancer Care Center

Position : Head of section of hematology, BMT program

Date : 07/2007- 03 /2013

Institution: Palestinian Ministry of Health-Beit-Jalla Hospital

Position : Consultant, Medical Oncologist

Date : 04/2013-07/2013

Institution: Sheba Medical Center.

Position : Staff physician

Date : 07/2013-02/2016

Institution: King Hussein Cancer Center

Position: Consultant, Medical Oncologist, Consultant Bone Marrow Transplantation and Cell Therapy.

Date : 02/2016-till present time.

5. Boards and certificates:

Board Name: Jordanian Board first step in Internal Medicine, 2003.

Board Name: Jordanian Board of Medical Oncology, 2007.

Board Name: Palestinian Board in medical Oncology hematology, 2007.

6. Additional Certificates:

License Name: Jordanian License of hematology oncology, Jordan, 2003-2007.

License Name: Palestinian License of hematology oncology, Palestine, 2007-2015

License Name: License of Hematology -Hadassah Hospital, Palestine, 2008 2015

License Name: License of Medicine-Sheba Medical Center, 2013-2014.

License Name: License of Medicine-Sheba Medical Center, 2014-2016.

License Name: License of Medicine-King Hussein Cancer Center, 16-2021.

License Name: License of Medicine-King Hussein Cancer Center,2022

7. Additional Certifications:

1. Statistics certificate, Amman, Jordan,2022
2. AHA BLS Course at King Hussein Cancer Center, ACLS Medical Center 2022-2023
3. Health Technology Assessment and Economic Evaluation certificate-KHCC, 2018
4. AHA BLS Course at King Hussein Cancer Center, ACLS at Sheba Medical Center, 2015-2018.
5. MSKCC and AUB joint course in oncologic sciences, 2013.
6. ACLS at AVH CCC, 2012.
7. ACLS at Makassed Islamic Charitable Hospital, 2000.

8. Committees and Memberships:

1. Pharmacy and Therapeutics Committee member-KHCC, 2019-2023
2. CART-Cell Committee-KHCC 2022-2023
3. IRB Committee Member-KHCC 2018-2023
4. VAD Committee Member-KHCC, 2016-2023
5. American Society of Hematology (ASH), 2022-2023
6. European Hematology Association (EHA), 2022-2023
7. Arab Medical Association against Cancer (AMAAC), 2007-2023

8. Jordanian Hematology society, 2022-2023
9. Palestinian Oncology Society (POS), 2007-2023
10. Deputy chair, Palestinian Oncology Society (Present), 2017-2019.
11. Head of National Breast Cancer Committee (former), 2013-2016.
12. Head of Transfusion committee at AVH (former), 2014-2016.
13. Head of therapeutics committee at AVH (former), 2014-2016.

9. **Conference participation:**

1. KHCC research Meeting, Amman-Jordan, Oct 2022, attendance
2. Advances in GvHD prevention and Therapy, ECP October 2022, attendance
3. Asia-Pacific BMT2022 conference 6-8 October 2022, presenter on
4. Diagnosis and management of poor graft function.
5. EBMT 2020, Poster Presentation. High incidence of GvHD with
6. TBF conditioning 2020.
7. Euro-Asian Hematology Congress, Istanbul, Turkey Speaker,
8. Is maintenance needed post-transplant? 2019.
9. Euro-Asian Hematology Congress, Istanbul, Turkey Speaker
10. Hypomethylating agents post allogeneic stem cell transplantation for high risk MDS and AML 2018 October.
11. Palestinian Medical Association meeting 2018, Establishing BMT program in Palestine 2018.
12. Euro-Asian Hematology Congress, Istanbul, Turkey Speaker, GVHD update 2017
13. Euro-Asian Hematology Congress, Antalya-Turkey-Speaker on
14. Mantle Cell Lymphoma 2016

15. Euro-Asian Hematology Congress-Antalya-Turkey-Speaker (How I manage DLBL)-2015
16. 12th and 13th AMAAC meetings as moderator of lymphoma session, 2012, 2013.
17. EBMT, poster presentation, presenter-2006
18. First Palestinian Hematology Symposium 2011 in Jerusalem at Augusta Victoria Hospital, President.
19. First Palestinian Oncology congress, Organizer 2010.
20. Second Palestinian Oncology Congress, Organizer 2011
21. International breast Cancer Conference at KHCC, presenter 2003.

11. Workshops Participation:

1. ATG use in HSCT: Clinical Trials and updated Guidelines, JHS, December 2022
2. Educational Course Clinical Trial Statistics for Non-Statisticians, Amman, Jordan, 15-17 November 2022
3. ALL-Mini-symposium from induction to CART and between 2022
4. Initial Orientation, KHCC, held on July 25, 2018
5. GCP Training for IRB Members Workshop held on Feb 25th, 2018.
6. Biosimilar Development and Ethical Considerations Workshop held on Dec. 19th, 20th.

12. Research Activities National:

1. T-Cell repertoire after allotransplant using post-transplant cyclophosphamide in patients with lymphoma previously exposed to Pembrolizumab. Intramural Grant-approved March 2022. **Ongoing**
2. A prospective, Randomized, Controlled Trial Comparing the administration of Post-Transplant Cyclophosphamide and the standard of care regimen for GVHD prophylaxis in Myeloablative Matched Related Allogeneic, Using Peripheral Blood Stem Cell Transplantation in Hematologic Malignancies. Intramural Grant-approved March 2022. **Ongoing.**

3. Conventional and Molecular Genetic Landscape among Jordanian Acute Lymphoblastic Leukaemia Patient, ongoing
4. AML in Jordan: Analysis According to the European LeukaemiaNet 2017 Cytogenetic Classification and survival outcome. Retrospective dataset, **Typescript in preparation.**
5. survival outcomes of 121 AML patients according to ELN AML 2022 classification from Jordan: Retrospective single center analysis.
6. TP53 abnormalities: Unraveling genetics complexity in adult acute lymphoblastic leukemia. Retrospective dataset,2022, **ongoing**
7. NOTCH1/FBXW7/RAS/PTEN-P53 Oncogenetic combinations: the unknown Prognostic Implications in Adult T-Cell Acute Lymphoblastic Leukemia. Retrospective dataset,2022, **ongoing**
8. Research support: Intramural grant-KHCC, PI, Post allogeneic
9. Azacitidine for high risk MDS and AML, Febr/2019-March 2020. Role: To define the role of Azacitidine in decreasing relapse risk in MDS/AML patients. Intramural Grant-approved March 2020.**Ongoing**

a Research Activities International:

A phase III randomized open-label multi-center study of Ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft vs host disease after allogeneic stem cell transplantation (REACH 3), Local Co-investigator. Oncology Clinical Protocol CINC424D2301 (INCB 18424365), Release date 20-Dec2017. Completed accrual, preliminary results published.

13. Publications and presentations:

Original articles:

1. **Haladleh KA**, Ma'koseh M, Sultan I, Rimawi DH, Muradi E, Gale RP. High incidences of acute and chronic graft-versus-host disease after

haematopoietic cell transplants for acute myeloid leukaemia using thiotepea, busulfan and fludarabine pretransplant conditioning. Acta Haematol. **2022** Nov 29.

2. **Halahleh K**, Al Rimawi D, Abu Ghosh A, Muradi I, Da'na W, Hamadani M. The Impact of Post-Hematopoietic Stem Cell Transplant Tyrosine Kinase Inhibitors in Philadelphia-Positive Acute Lymphoblastic Leukemia. Hematol Oncol Stem Cell Ther. **2022** Dec 23;15(4):219-222.
3. **Khalid Halahleh** , Suhaib Al Sawajneh , Yacob Saleh , Omar Shahin , Alaa Abufara , Mohamad Ma'koseh , Rashid Abdel-Razeq , Fareed Barakat , Hadeel Abdelkhaleq , Nadira Al-Hassan , Reem Atiyyat , Noor Al-Faker , Zaid Omari , Hamza Ghatasheh , Imad Jaradat , Isa Muradi , Sultan Iyad, Ali Bazarbachi. Pembrolizumab for the Treatment of Relapsed and Refractory Classical Hodgkin Lymphoma After Autologous Transplant and in Transplant-Naïve Patients.
4. **Halahleh K**, Ma'koseh M, Rawashdeh M, Barakat F, Odai AA, Nofal A, Lina H, Muradi I and Akram Al. PD-1 Blockade with Pembrolizumab in Relapsed/ Refractory Primary Mediastinal B-Cell Lymphoma. Annals of Clinical Case Reports. 08 Jul, **2022**.
5. Akram Al-Ibraheem , Farah Anwer , Malik E Juweid , Qaid Ahmed Shagera , Aysar N Khalaf , Shahed Obeidat, Areen Mansour , Mohammad Ma'koseh , **Khalid Halahleh** , Imad Jaradat , Nidal Almasri , Asem Mansour. Interim FDG-PET/CT for therapy monitoring and prognostication in Hodgkin's Lymphoma. Sci. Rep. **2022** Oct 21;12(1): 17702.

6. **Khalid Halahleh** , Ayat Taqash , Hadeel Abdelkhaleq , Mohamad Manasrah , Lina Marie , Kamal Al-Rabi. Analysis of FLT3-Activating Mutations in Patients With Acute Myelogenous Leukemia in Jordan: Association With FAB Subtypes and Identification of Subgroups With Poor Prognosis. Halahleh K, et al. Clin Lymphoma Myeloma Leuk. **2021**.

7. **Khalid Halahleh** , Yazan Alhalaseh , Dalia Al-Rimawi, Waleed Da'na , Kamal Alrabi , Nazmi Kamal , Isra Muradi , Hikmat Abdel-Razeq. Extramedullary acute myeloid leukemia (eAML): Retrospective single center cohort study on clinico-pathological, molecular analysis and survival outcomes. Halahleh K, et al. Ann Med Surg (Lond). **2021**.

8. Mohammad Ma'koseh , Faris Tamimi , Alaa Abufara , Lana Abusalem , Osama Salama , Yacob Saleh , Rnad Khader , Baha A Faiyoumi , Mohammad Al-Rwashdeh , **Khaled Halahleh**· Impact of Central Nervous System International Prognostic Index on the Treatment of Diffuse Large B Cell Lymphoma. Cureus. **2021**.

9. Abdel-Razeq H, Ma'koseh M, Mansour A, Bater R, Amarin R, Abufara A, **Halahleh K**, Manassra M, Alrwashdeh M, Almomani M, Zmaily M. The Application of the ThroLy Risk Assessment Model to Predict Venous Thromboembolism in Patients with Diffuse Large B-Cell Lymphoma. Clin Appl Thromb Hemost. **2021** Jan-Dec; 27:10760296211045908.

10. Mohammad Ma'koseh , Rula Amarin , Faris Tamimi , Baha' Sharaf , Alaa Abufara , Omar Shahin , Mohammed K M Manassra , **Khalid Halahleh**. Treatment of adult Burkitt lymphoma with the CALGB 1002 protocol: a single center experience in Jordan. Ma'koseh M, et al. Blood Res. **2021**.
11. **Khalid Halahleh** , Robert Peter Gale , Waleed Da'na , Mohammad Ma'koseh , Salwa Saadeh , Waseem Alan , Dana Yousef , Rozan Al-Far , Isra Muradi , Husam Abujazar , Hasan Hashem · Therapy of post-transplant poor graft function with eltrombopag. Bone Marrow Transplant. **2021**.
12. Mohammad Ma'koseh*¹MohammadAl-Essa¹, HusamAbu-Jazar¹, **Khalid Halahleh**¹Walid Daana, ¹Rozan Al-Far¹, Salwa Saadeh. Outcomes of Patients with Multiple Myeloma Following Autologous Stem Cell Transplant According to Post-Transplant Time of Response: A Single Center Experience of 148 Consecutive Transplants. Clinical Lymphoma Myeloma and Leukemia. Volume 19, Supplement 1, September **2019**, Page S329
13. **Khalid Halahleh** , Mahmoud M Sarhan , Robert Peter Gale , Hasan Hashem , Eman Khattab , Waleed Da'na , Mohammad Ma'koseh , Mayada Abu Shanab , Maha Yousef , Laiali Khalil , Nilly Hussein · Shanta Sharma , Husam Abujazar , Rawad Rihani , Abdelghani Tbakhi , Abdulla Al Abadi. Hematopoietic cell transplants in Jordan: Different indications than the US and EU. K. Halahleh, Bone Marrow Transplant. **2018**.
14. **Khalid Halahleh** , Mohammad Ma'koseh , Husam Abu-Jazar , Sameer Yaser , Hani Howar , Mohamad Al-

Rawashdeh, Abdelghani Tbakhi , Rula Najjar , Nilly Hussein , Dalia Al-Rimawi , Robert Peter Gale, Mahmoud Sarhan. High-dose chemotherapy and autotransplants for plasma cell . K.

Halahleh. Bone Marrow Transplant. **2018** Oct; 53(10):1349-1350.

15. **Khalid Halahleh** , Robert Peter Gale. Cancer care in the Palestinian territories. Halahleh K, Gale RP . Lancet Oncol. **2018** Jul;19(7): e359-e364. doi: 10.1016/S1470-2045(18)30323-1.
16. Robert Peter Gale, **Khalid Halahleh** · Cancer care in the Palestinian territories, ASCO Post **2018**.
17. **Halahleh Khalid**, Dahabreh Laith, Manasrah Mohamad, Sarrawi Tahani, Rihani Rawad, Ma'koseh Mohammad, Abu Jazar Husam, Abdelghani Tbakhi and Sarhan Mahmoud. High-Dose Therapy and Autologous Hematopoietic Progenitor Cells Transplantation for Relapsed or Refractory Hodgkin Lymphoma: A follow up analysis of King Hussein Cancer Center Results and Prognostic Variables. Trends in transplantation Journal July **2018**.
18. **Halahleh Khalid**, Gale RP, Nagler A Isochromosome X in Myelodysplastic Syndrome.. Acta Haematol. **2016**; 135(1):378.
19. **Halahleh Khaled**, MD, Bilan Salem, MD, Abde-shafi Omar, MD, Hawamdeh Omar, RN Sabatin Fuad, MD. Incidence and Prevalence of ER, PR, Her-2 Neu of Breast cancer in Palestine, single center Experience, PAJO, **2011**.

Books and Chapters

Khalid Halahleh, Niveen M. E. Abu Rmeileh & Mohammad M. Abusrour. Cancer in the Arab World. Editors: Humaid O. Al-Shamsi Ibrahim H. AbuGheida Faryal Iqbal Aydah Al-Awadhi. General Oncology Care in Palestine. First Online: 16 March **2022**. ISBN978-981-16-7944-5 ISBN978-981-16-7945. <https://doi.org/10.1007/978-981-16-7945-2>

14. Original Abstracts and podium oral presentation:

1. K. Halahleh, E. Alnaimi, E. Danoun, I. Muradi, M. Horani, M. Makoseh, I. Sultan. Frequency and impact of pre-transplant somatic mutations on clinical outcomes of AML patients receiving allogeneic Hematopoietic Stem Cells Transplantation. Submitted Dec 2022 to EBMT **2023**.
2. **Khalid Halahleh**. The Impact of Graft CD 3+ T-Cell Dose on the Outcome of T-Cell-Replete HLA-mismatched Allogeneic Peripheral Blood Stem Cell Transplantation in Advanced Hematologic Malignancies. KHCC Research Conference November **2022(Oral)**.
3. Rawan Mustafa, MD, Dalia Al-Rimawi, MSc, Dania Sarhan, BSc, Hadeel Abdelkhaleq, BSc, **Khalid Halahleh, MD**. CT-098 Impact of T-Cell Dose on Outcome of T Cell–Replete HLA-Mismatched Allogeneic Peripheral Blood Stem Cell Transplantation. Clinical Lymphoma Myeloma and Leukemia. Volume 22, Supplement 2, **October 2022(Oral)**
4. **Khalid Halahleh MD**, Mohammad Ma'koseh MD, Isra Murad MD, Ayat Taqash BSc, Anas Zayed MD. AML-463 AML in Jordan: Analysis According to 2017 European LeukemiaNet Risk Stratification. Clinical

Lymphoma Myeloma and Leukemia. Volume 22, Supplement 2, **October 2022**, Page S253(Poster).

5. Mohammad Ma'koseh MD, Suhaib Khater MD, Heba Farfoura MD, Yumna Khatib MD, Zaid Omari MD, Hazim Ababneh MD, Baha Faiyoumi MD, AyatTaqash BSc, Alaa Abufara MD, Omar Shahin MD, Yacob Saleh MD, **Khalid Halahleh MD**, Kamal Alrabi MD. ABCL-242 Definition of Bulky Disease in Early-Stage Diffuse Large B-Cell Lymphoma on Longitudinal and Axial Planes. Clinical Lymphoma Myeloma and Leukemia. Volume 22, Supplement 2, October **2022**, Page S365(poster)
6. **Khalid Halahleh**. Survival outcomes of 121 AML patients according to ELN AML 2022 classification from Jordan: Retrospective single center analysis. KHCC Research Conference November **2022**(Poster).
7. **Khalid Halahleh**. Pembrolizumab for the treatment of relapsed and refractory classical Hodgkin lymphoma after autologous transplant and in transplant-naïve patients. EBMT **2022**(Poster).
8. Clinical Outcomes of COVID-19 in Hematological Malignancies in
9. Jordan: Tertiary Cancer Center Experience. Blood (**2021**) 138
10. (Supplement 1): 5039.<https://doi.org/10.1182/blood-2021-154509>(Poster).
11. P-236 Pembrolizumab and allotransplants for relapsed Hodgkin Lymphoma. EBMT **2022**(Poster).
12. The outcome of allotransplant using TBF conditioning from matched sibling related donors in high-risk myelodysplasia and acute myeloid

leukemia: A retrospective single center experience [A-1137-0001-01459], EBMT **2020**(Poster).

13. Therapy of post-transplant poor graft function with Eltrombomag. EBMT **2019**(Poster).
14. Mohammad Ma'koseh,¹ Mohammad Al-Essa,¹ Husam Abu Jazar,¹ **Khalid Halahleh**,¹ Walid Daana,¹ Rozan Al-Far,¹ Salwa Saadeh. Outcomes of Patients with Multiple Myeloma Following Autologous Stem Cell Transplant According to Post-Transplant Time of Response: A Single Center Experience of 148 Consecutive Transplants. Clinical Lymphoma Myeloma and Leukemia. Volume 19, Supplement 1, September **2019**, Page S329(Poster)
15. Outcome of patients with multiple myeloma following autologous stem cell transplantation according to post-transplant time of response: single center experience of 148 consecutive transplants. SOHO **2019**, coauthor(Poster).
16. Secondary Tumors following Hematopoietic Stem Cell Transplantation:
17. 15 years' Experience from King Hussein Cancer Center, accepted to SIOF **2019**, coauthor(Poster).
18. Myeloablative versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome: single center experience. EBMT **2018**(Poster).
19. The outcome of allogeneic stem cell transplantation in patients with high risk MDS and AML: single center experience. EBMT **2018**(Poster).

20. The outcome of High dose chemotherapy and autologous stem cell transplantation in transplant-eligible patients with Multiple Myeloma, Real life story. EBMT **2017**(Poster).
21. Hematopoietic Stem Cell Mobilization: Predicting the Unpredictable. EBMT 2017. Blood and Marrow Transplantation Program Experience at King Hussein Cancer Center. EBMT **2017**(Poster).
22. High-Dose Therapy and Autologous Hematopoietic Progenitor Cells Transplantation for Relapsed or Refractory Hodgkin Lymphoma: A follow up analysis of King Hussein Cancer Center Results and Prognostic Variables. EBMT **2017**(Poster).
23. Allogeneic transplantation in Myelofibrosis in infancy. KHCC, Abstract, oral presentation, EBMT **2006**(Oral).
24. Establishment of haploidentical donor marrow transplantation program at KHCC, EBMT **2019**(Poster).
25. Pediatric haploidentical and cord blood transplantation: A single center experience, Coauthor, EBMT **2019**(Poster)
26. Comparable efficacy of peripheral stem cell mobilization using biosimilar Filgrastim Nivestim® to original Neupogen® in healthy donors, Coauthor, EBMT **2019**(Poster).
27. Simply deceptive: can single spreadsheet perform all calculations related to cell collection and processing, monitor quality control and become a running product inventory database, Coauthor, EBMT **2019**(Poster).

28. Interferon-Gama as an early biomarker to predict *GvHD* in allogeneic hematopoietic stem cell transplanted patients, Coauthor, EBMT **2019**(Poster).

1. **Manuscripts submitted:**

1. **Khalid Halahleh¹**, Yasuyuki Arai², Eleni Gavriilaki³ Diagnosis and management of Poor Graft Function. Blood Cell Therapy Journal, accepted Dec **2022**.
2. **Khalid Halahleh MD¹**; Rawan Mustafa MD²; Dalia Al Rimawi³, Hadeel Abdelkhaleq³, Isra Muradi⁴; Iyad Sultan MD⁵. The Impact of graft CD3+T-cell Dose on The Outcome of T-Cell Replete HLA-Mismatched Allogeneic Hematopoietic Peripheral Blood Stem Cells Transplantation. accepted in Journal of Hematology (JH). 16 dec **2022**. www.thejh.org
3. **Khalid Halahleh¹**, Abeer Yaseen¹, Isra Muradi², Akram Al-Ibraheem³, Eyad Sultan⁴, Mohammad Ma'koseh¹. Outcome of Primary Mediastinal Large B Cell Lymphoma Treated with RCHOP. Accepted in Journal of Blood Medicine Dec **2022**.
4. Khalid Abdel-Rahman Halahleh MD¹; Mohammad Salah Makoseh MD¹; Ayat Mohamad-Amin Taqash²; Fawzi Jamil Abuhijla MD³; Lubna Suleiman Ghatasheh MD⁵; Rozan Bassam Al Far MD¹; Lina Mahmoud Wahbeh MD³; Isra Faraj Muradi MD⁴; Abdelatif Mohamad Almousa MD³; Hasan Kamal Hashem MD⁵; Ramiz Ahmad Abu-Hijli MD³. Prophylactic Cranial Irradiation for Acute Lymphoblastic Leukemia: To Boost or Not To Boost, submitted to Radiation oncology journal Dec **2022**.

16. References:

Asem H. Mansour, MD,

CEO/Director General

King Hussein Cancer Center

P.O. Box 1269 Aljubeiha

Amman, 11941 Jordan

Tel. (+962)-6-530-0460

Amansour@khcc.jo

Hikmat N. Abdel-Razeq, MD.

CMO, and Chairman Department of Internal Medicine

King Hussein Cancer Center

Amman 11941Jordan

Tel: 009626-5300640, **ext:** 1000 **Fax:** 00962-6-5353001

habdelrazeq@khcc.jo

Mahmoud Sarhan, MD, MM, CPE

1st CEO, Saudi Jordanian Fund for Medical and Education Investments

Prof. of Pediatrics, Medical oncology, hematology, and stem cell transplantation.

Amman-Jordan

Cell: 00962-797588822

Sarhan1954@gmail.com

Huda Salman, MD, PhD,

Don Brown Chair in Immunotherapy and professor of medicine
Department of Medicine, Division of Hematology and Oncology
IU School of Medicine,

Locil1970@yahoo.com

ALJURF, MAHMOUD DEEB SAEED M

Prof. of Medicine, and Hematology, Stem Cell Transplant & Cellular Therapy
Director, Bone Marrow Transplantation Program

Deputy Director of Cancer Center

King Faisal Specialty Hospital and Research Center

KSA-Riyad maljurf@kfshrc.edu.sa

Robert Peter Gale MD, PhD, DSc(hc), FACP, FRCP, FRSM

Haematology Research Centre, Division of Experimental

Medicine, Department of, Medicine, Imperial College

London, London, UK robertpetergale@gmail.com